Lv3
336 积分 2025-05-26 加入
Targeting PRMT5 to Circumvent Acquired Ibrutinib Resistance in Mantle Cell Lymphoma
1天前
求助中
PRMT5 is upregulated by B-cell receptor signaling and forms a positive-feedback loop with PI3K/AKT in lymphoma cells
1天前
已完结
Biomarker-driven development of new therapies for autoimmune diseases: current status and future promises
14天前
已完结
Treating Human Autoimmunity: Current Practice and Future Prospects
14天前
已完结
Efficacy, Safety, and Pharmacodynamic Effects of the Bruton’s Tyrosine Kinase Inhibitor Fenebrutinib (GDC‐0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial
16天前
已完结
POS1079 Pharmacodynamic Response of JNJ-77242113 in Serum and Skin of Patients with Moderate-to-Severe Psoriasis: 1-Year Results from FRONTIER 1 & 2
18天前
已关闭
POS1137 PHARMACOKINETICS AND EXPOSURE-RESPONSE RELATIONSHIPS OF UPADACITINIB OR ELSUBRUTINIB ALONE OR IN COMBINATION (ABBV-599) IN SYSTEMIC LUPUS ERYTHEMATOUS
1个月前
已完结
ABBV-105, a selective and irreversible inhibitor of Bruton’s tyrosine kinase, is efficacious in multiple preclinical models of inflammation
1个月前
已完结
Kinase inhibition in autoimmunity and inflammation
1个月前
已完结
Endothelin receptor antagonists in chronic kidney disease
1个月前
已完结
皖公网安备34019202002308
